PSA Levels and the Probability of Prostate Cancer on Biopsy

Slides:



Advertisements
Similar presentations
Volume 56, Issue 5, Pages (November 2009)
Advertisements

Volume 61, Issue 3, Pages (March 2012)
Volume 50, Issue 3, Pages (September 2006)
Volume 41, Issue 6, Pages (June 2002)
The PSA Era is not Over for Prostate Cancer
Volume 51, Issue 2, Pages (February 2007)
Breast, prostate, and thyroid cancer screening tests and overdiagnosis
Testosterone Therapy in Men With Prostate Cancer
Prostate Cancer 2008: Challenges in Diagnosis and Management
Prostate Cancer: Highlights from 2006
Volume 51, Issue 6, Pages (June 2007)
Volume 73, Issue 5, Pages (May 2018)
Volume 73, Issue 6, Pages (June 2018)
Volume 68, Issue 1, Pages (July 2015)
Bladder Cancer: A Major Public Health Issue
Nomograms for Bladder Cancer
HERBERT C. RUCKLE, M. D. , GEORGE G. KLEE, M. D. , PH. D. ,, JOSEPH E
Volume 60, Issue 5, Pages (November 2011)
Towards Early and More Specific Diagnosis of Prostate Cancer
Diagnostic Strategies for Prostate Cancer
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Luis Martínez-Piñeiro  European Urology Supplements 
The PSA Era is not Over for Prostate Cancer
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Volume 54, Issue 3, Pages (September 2008)
Volume 65, Issue 6, Pages (June 2014)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Richard C. Harkaway  European Urology Supplements 
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Volume 50, Issue 5, Pages (November 2006)
Prostate-Specific Antigen, Digital Rectal Examination, and Transrectal Ultrasonography: Their Roles in Diagnosing Early Prostate Cancer  MICHAEL R. CUPP,
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Volume 55, Issue 3, Pages (March 2009)
Prostate Cancer Nomograms: An Update
The Importance of Testosterone Control in Prostate Cancer
Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis
Jacques Irani  European Urology Supplements 
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Volume 49, Issue 4, Pages (April 2006)
Long-Term Hormonal Therapy: Who Would Benefit?
Volume 59, Issue 4, Pages (April 2011)
The Hallmarks of BPH Progression and Risk Factors
How and When to Take Prostate Biopsies
Sergio Bracarda  European Urology Supplements 
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology.
Thomas Steuber, Matthew Frank O'Brien, Hans Lilja  European Urology 
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
Volume 74, Issue 6, Pages (December 2018)
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Prostate Cancer 2008: Challenges in Diagnosis and Management
Richard Berges  European Urology Supplements 
Axel Heidenreich  European Urology Supplements 
Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid  Theresa A. Guise,
The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review  Fritz Schröder,
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Volume 74, Issue 6, Pages (December 2018)
Volume 51, Issue 2, Pages (February 2007)
Volume 54, Issue 3, Pages (September 2008)
Oncoforum Urology: Prostate Cancer 2008 at a Glance
HERBERT C. RUCKLE, M. D. , GEORGE G. KLEE, M. D. , PH. D. ,, JOSEPH E
Epidemiology and Demographics of Prostatitis
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Axel Heidenreich  European Urology Supplements 
Does PSA Testing Influence the Natural History of Prostate Cancer?
Nomogram depicting estimates of postprogression survival, including estimates of 6-, 12-, and 24-month OS according to prechemotherapy and postchemotherapy.
Michael Marberger  European Urology Supplements 
Presentation transcript:

PSA Levels and the Probability of Prostate Cancer on Biopsy Matthew B Gretzer, Alan W Partin  European Urology Supplements  Volume 1, Issue 6, Pages 21-27 (September 2002) DOI: 10.1016/S1569-9056(02)00053-2

Fig. 1 PSA density values for detecting prostate cancer. Logistic regression demonstrating PSAD for detecting cancer in men with PSA values 4.0–10.0ng/ml and palpably normal prostate. Adapted with permission from Seamen and Whang [28] (Saunders, Mosby). European Urology Supplements 2002 1, 21-27DOI: (10.1016/S1569-9056(02)00053-2)

Fig. 2 Probability of prostate cancer by total PSA level. Flow chart of probability of prostate cancer based on presenting PSA level. European Urology Supplements 2002 1, 21-27DOI: (10.1016/S1569-9056(02)00053-2)

Fig. 3 Nomogram predicting the probability of a positive prostate biopsy. Directions: Locate the patients age on the age axis. Draw a straight line upward to the points axis to determine how many points toward the probability of a positive prostate biopsy the receives for age. Repeat the process for PSA. Sum the points. If the patient is African American, add an additional two points. Locate the final sum for age, PSA, and race on the total points axis. Draw a straight line down to find the patient’s probability of having a positive prostate biopsy. Adapted with permission from Eastham et al. [50] (Elsevier, Amsterdam). European Urology Supplements 2002 1, 21-27DOI: (10.1016/S1569-9056(02)00053-2)